Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV

Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV

Background: The aim of the study is to evaluate the effectiveness, safety, and tolerability of a two-drug regimen (2-DR) dolutegravir/lamivudine (DTG/3TC) versus a three-drug regimen (3-DR) tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in a real-life cohort of HIV-1 virologically sup...

Full description

Bibliographic Details
Main Authors: Giuseppe Vittorio De Socio, Sara Tordi, Debora Altobelli, Anna Gidari, Anastasia Zoffoli, Daniela Francisci
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Journal of Clinical Medicine
Subjects:
HIV
dolutegravir
bictegravir
virological failure
safety
toxicity
Online Access:https://www.mdpi.com/2077-0383/12/24/7759

Internet

https://www.mdpi.com/2077-0383/12/24/7759

Similar Items